Xvivo Perfusion AB (publ) (XVIPY) Comparison with companies in other sectors?

Xvivo Perfusion AB (publ) has a share price of 126.00M. You can analyze Xvivo Perfusion AB (publ) (XVIPY) competitors across different market sectors through stock heatmaps.

What are XVIPY's NET and operating margins?

Xvivo Perfusion AB (publ) (XVIPY) operating margin is around 0.06, and net profit margin is approximately 0.27 as of the latest reports.

In what way does XVIPY's earnings per share (EPS) trend reflect its financial momentum?

Xvivo Perfusion AB (publ) (XVIPY) EPS is N/A (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Xvivo Perfusion AB (publ) is N/A, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Xvivo Perfusion AB (publ)?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Xvivo Perfusion AB (publ) like P/E which is 33.44, P/B which is 3.28, and PEG which is 0.05. Compare them with sector averages to evaluate if the stock is priced fairly.

Xvivo Perfusion AB (publ)

XVIPY•PNK

Healthcare

Medical - Specialties

$5.70

$5.70(4.552715654952077e+29%)

Fundamental Analysis of Xvivo Perfusion AB (publ) (XVIPY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

P/E Ratio

ROE

0.10%

Net Margin

0.27%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$718.19M

Shares OutstandingTotal number of shares issued

$126.00M

Book Value/ShareNet worth per share

$66.13

Revenue/ShareAnnual revenue per share

$23.83

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

Net MarginNet income as percentage of revenue

27.21%

Operating MarginOperating income as percentage of revenue

6.36%

ROEReturn on shareholders' equity

10.14%

ROAReturn on total assets

8.97%

ROCEReturn on capital employed

2.24%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.33

Cash/ShareCash and equivalents per share

$14.29

FCF YieldFree cash flow as percentage of market cap

0.15%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for XVIPYFinancial Ratios Analysis details for XVIPY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for XVIPYSector Benchmarking details for XVIPY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Xvivo Perfusion AB (publ) Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Xvivo Perfusion AB (publ). Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Xvivo Perfusion AB (publ)'s unique business strengths and challenges.

Key Financial Metrics for Xvivo Perfusion AB (publ)

For Xvivo Perfusion AB (publ), essential financial indicators include EPS -, PE -, and ROE 0.10. These key ratios reveal insights into Xvivo Perfusion AB (publ)'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Xvivo Perfusion AB (publ) with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Xvivo Perfusion AB (publ)

Metrics like Net Margin 27.21% and ROA 8.97% shed light on how well Xvivo Perfusion AB (publ) is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Xvivo Perfusion AB (publ) can sustain its operations and continue growing in the future.

Valuation and Market Position of Xvivo Perfusion AB (publ)

Using ratios such as P/B Ratio 3.28 and PEG Ratio 0.05, investors can assess whether Xvivo Perfusion AB (publ) is appropriately valued based on its financials and growth potential. These figures, combined with Xvivo Perfusion AB (publ)'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Xvivo Perfusion AB (publ)

Financial health indicators, such as Debt/Equity Ratio 0.005 and Cash Flow $0.33, provide a snapshot of Xvivo Perfusion AB (publ)'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Xvivo Perfusion AB (publ), is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Xvivo Perfusion AB (publ)

Investing in Xvivo Perfusion AB (publ) based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Xvivo Perfusion AB (publ) focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;